News | July 04, 2007

Medipattern, HealthCareIQ Team Up to Support Reimbursement Process for B-CAD

July 5, 2007 - Medipattern Corp., developer of computer-aided diagnosis (CAD) solutions for breast ultrasound imaging, announced a strategic alliance with HealthcareIQ LLC, reaching an agreement where Medipattern’s clients will have access to payer-specific benefit plan rules, coding guidelines and medical necessity protocols.

To date, the alliance has benefited Medipattern’s clients through both claims submission support and the successful receipt of reimbursements for the reporting of findings used to evaluate and manage patient care and provide diagnostic indicators that substantiate evidenced-based medicine, all obtained through use of B-CAD. Nationally recognized healthcare insurance companies are paying for the supervision of the B-CAD evaluation and management procedure for reporting and review by radiologists.

“B-CAD is a procedure performed on outpatients using breast ultrasound images and as such is reimbursable under the American Medical Associations (AMA) Common Procedure Terminology (CPT) code guidelines for evaluation and management procedures,” said Arthur Gelber, president and CEO of HealthcareIQ.

“B-CAD includes an automated workflow that naturally follows the radiologists’ process for correctly classifying lesions into corresponding American College of Radiology (ACR) Breast Imaging Reporting And Data System (BI-RADS) terminology, which forms the basis for evidence-based reporting and compliance with not only the ACR but payers’ guidelines for appropriate billing and reporting requirements. B-CAD’s ability to convert the details captured during the review of ultrasound breast images in a natural language report helps reduce the need for transcription as well as providing a comprehensive record for physicians to track patient progress as they manage the patients’ care. Breast care clinics need to be able to track subtle changes over the course of years to provide adequate patient care. B-CAD uses the ACR BI-RADS lexicon for evaluation of lesions and its structured reporting provides the necessary framework for evidence of tracking care over the long term,” stated Jeff Collins, CEO of The Medipattern Corporation.

For more information: www.medipattern.com

Related Content

QView Medical Showcases QVCAD for ABUS Exams at RSNA 2018
News | Ultrasound Women's Health | November 19, 2018
QView Medical will showcase QVCAD, the first U.S. Food and Drug Administration (FDA)-approved artificial intelligence (...
Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
iCAD Announces Positive Clinical Results for Artificial Intelligence Tomosynthesis Technology
News | Mammography | October 11, 2018
iCAD Inc. announced positive clinical results of its new digital breast tomosynthesis (DBT) cancer detection software,...
SimonMed Deploys ClearRead CT Enterprise Wide
News | Computer-Aided Detection Software | September 17, 2018
September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologie
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Riverain Technologies Issued U.S. Patent for Vessel Suppression Technology
News | Computed Tomography (CT) | June 14, 2018
Riverain Technologies announced that the United States Patent and Trademark Office (USPTO) has awarded the company a...
FDA Issues Proposed Order to Reclassify Certain Radiological Medical Image Analyzers
News | Computer-Aided Detection Software | June 01, 2018
The U.S. Food and Drug Administration (FDA) is issuing a proposed order to reclassify certain radiological medical...
Median Technologies and the Nice University Hospital to Use AI in Lung Cancer Screening
News | Artificial Intelligence | March 15, 2018
March 15, 2018 – Median Technologies, the industry-leading Imaging Phenomics Company and the Nice University Hospital
FDA Clears First AI-Powered Clinical Decision Support Software for Stroke
Technology | Clinical Decision Support | February 14, 2018
The U.S. Food and Drug Administration (FDA) announced marketing clearance for Viz.AI’s Contact application, the first ...